Articles
Volume 9 Supplement 1
Proceedings of the 2009 Drug Discovery for Neurodegeneration Conference
Proceedings
Drug Discovery for Neurodegeneration Conference
Washington, DC, USA
2-3 February 2009
Edited by Diana W Shineman and Howard M Fillit
The conference and the publication of these proceedings were supported by conference grant U13-AG031125 from the National Institute on Aging, the National Institute of Neurological Disorders and Stroke and the National Institutes of Health's Office of Rare Diseases. Other sponsors: CoMentis, Eli Lilly and Company, sanofi-aventis, Biogen Idec and The Michael J. Fox Foundation for Parkinson's Research
|
Introduction
Meeting the unique challenges of drug discovery for neurodegenerative diseases Diana W Shineman, Howard M Fillit BMC Neurology 2009, 9(Suppl 1):I1 (12 June 2009) |
|
Proceedings
Katya Tsaioun, Michel Bottlaender, Aloise Mabondzo, the Alzheimer's Drug Discovery Foundation BMC Neurology 2009, 9(Suppl 1):S1 (12 June 2009) |
|
Proceedings
The basics of preclinical drug development for neurodegenerative disease indications Karen L Steinmetz, Edward G Spack BMC Neurology 2009, 9(Suppl 1):S2 (12 June 2009) |
|
Proceedings
Characteristics of compounds that cross the blood-brain barrier William A Banks BMC Neurology 2009, 9(Suppl 1):S3 (12 June 2009) |
